Clinical trials: Schizophrenia Prodrome
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Schizophrenia Prodrome
D-serine for the Schizophrenia Prodrome
The purpose of the study is to determine the safety and efficacy of D-serine as an early intervention treatment for the schizophrenia prodrome condition.
- Trial name
- NCT00826202
- Testing
- D-serine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia Prodrome
Glycine vs Placebo for the Schizophrenia Prodrome
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
- Trial name
- NCT00291226
- Testing
- Glycine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University